DocSpace was founded by Chief Product Officer Miles Montes (left) and CEO Mario Amaro, a physician and U.S. Navy Veteran. Photo courtesy of DocSpace

A Houston-based software company providing clinicians a turn-key platform for their practice has announced the close of its seed funding round.

DocSpace raised $1.2 million in seed funding led by Slauson & Co. with participation by Precursor Ventures, Acrew Capital's Scout Fund, and SputnikATX Ventures. The company's angel investors Nathan and Sonia Baschez, Nikhil Krishnan, and Eliana Murillo. The company was founded by CEO Mario Amaro, a physician and U.S. Navy Veteran, and Chief Product Officer Miles Montes, an expert in platform product management previously at ADP and ShopLatinx.

"Existing practice management software requires clinicians to manually self-navigate the expensive and complicated business formation process before they're able to utilize any of their product services," says Amaro in a news release. "When you require clinicians to do all the hard work of starting a new business then force them to purchase expensive software, it's no surprise that fewer clinicians have the opportunity to build new businesses in their communities."

Since its launch in March 2020, DocSpace has helped hundreds of clinicians, therapists, dentists, physicians, and optometrists build their practices with its end-to-end software that provides, according to the release, HIPAA-compliant tools like "digital health storefronts with custom themes to back office management tools like scheduling, video conferencing, banking, payroll, and bookkeeping."

"Making it easier for clinicians to start new businesses is critical to decreasing clinician burnout, giving more choices to patients, and reducing the amount of administrative and overhead bloat in delivering health services. We should treat clinicians like entrepreneurs and reduce the barriers to them striking out on their own," says Nikhil Krishnan, the founder of Out-Of-Pocket and adviser and investor to DocSpace.

The seed funding go toward building out DocSpace Pay, a payment system tool for patients and clinicians.

"This is why we were inspired by Shopify's business model and the infrastructure they created to empower retail merchants to be small business owners," says Amaro. "We are building the first clinical practice operating system that provides clinician entrepreneurs the opportunity to seek practice independence, helping them get to market faster, while leveling the playing field so they can compete against large hospital systems and other VC-backed healthcare startups."


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.